H1N1 Influenza: Symptoms and Treatment
For H1N1 influenza, initiate oseltamivir 75 mg twice daily for 5 days as soon as possible after symptom onset, ideally within 48 hours, for patients with fever >38°C and respiratory symptoms. 1
Clinical Presentation
H1N1 influenza presents with characteristic symptoms that distinguish it from other respiratory infections:
Primary Symptoms
- Fever (typically >38.5-39°C) - present in 96% of cases 2, 3
- Cough (usually dry) - occurs in 86-95% of patients 2, 4
- Respiratory symptoms: rhinorrhea (80-90%), sore throat (35%), dyspnea in severe cases 5, 4
- Systemic symptoms: myalgia (40%), malaise (78%), headache (66%), chills 3, 5
Distinguishing Features
- Gastrointestinal involvement occurs in up to 28-55% of H1N1 cases (nausea, vomiting, diarrhea), which is more common than in seasonal influenza 6, 5
- Myalgia appears specifically in H1N1-positive patients and is notably absent in H1N1-negative influenza cases 3
- Lymphopenia is characteristic, occurring in 82% of H1N1 cases versus only 24% in other influenza types 3
Severe Disease Indicators
Watch for progression markers requiring immediate escalation:
- Respiratory rate >24/min, oxygen saturation <90%
- Altered mental status
- Persistent fever with worsening dyspnea
- Elevated CK, LDH, CRP, and PCT levels (significantly higher in critical cases) 7
Treatment Algorithm
Antiviral Therapy - Primary Intervention
Oseltamivir is the first-line treatment 1, 6:
- Standard dose: 75 mg twice daily for 5 days
- Renal adjustment: 75 mg once daily if creatinine clearance <30 mL/min 2
- Severe/critical illness: Consider doubling to 150 mg twice daily 6
- Pediatric dosing: Weight-based (see guidelines for specific weights) 1
Treatment criteria 2:
- Acute influenza-like illness
- Fever >38°C (may be absent in immunocompromised/elderly)
- Ideally symptomatic ≤48 hours
Critical caveat: Unlike recommendations for healthy individuals, treat all suspected H1N1 cases regardless of symptom duration beyond 48 hours, especially in high-risk patients (immunocompromised, transplant recipients, pregnant women, chronic disease) 2, 6, 2. Prolonged viral shedding occurs in immunocompromised patients, justifying extended treatment 6.
Alternative Antiviral Options
Zanamivir (10 mg inhaled twice daily for 5 days) 1:
- Use when oseltamivir resistance suspected
- Contraindicated in underlying airway disease
- Requires ability to use diskhaler device properly
Avoid adamantanes (amantadine, rimantadine) - H1N1 strains are universally resistant 1, 6
Antibiotic Therapy - Secondary Bacterial Infection
Do NOT routinely prescribe antibiotics for uncomplicated H1N1 2. Add antibiotics only when:
Non-severe pneumonia 2:
- Oral co-amoxiclav or tetracycline preferred
- Alternative: macrolide (clarithromycin) or respiratory fluoroquinolone
Severe pneumonia 2:
- IV co-amoxiclav or 2nd/3rd generation cephalosporin (cefuroxime/cefotaxime) PLUS
- Macrolide (clarithromycin or erythromycin)
- Duration: 7 days for non-severe, 10 days for severe cases
Indications for antibiotics:
- Recrudescent fever or increasing dyspnea after initial improvement
- Radiographic pneumonia
- High-risk patients with lower respiratory features
Adjunctive Therapies - Generally NOT Recommended
Strong recommendation AGAINST 8:
- Antibiotics in non-severe influenza without bacterial superinfection
- Corticosteroids in severe influenza
- NSAIDs, macrolides (as adjunctive therapy), mTOR inhibitors
- Passive immune therapy
Supportive Care
- Antipyretics and fluids (avoid aspirin in children - Reye's syndrome risk) 2, 9
- Oxygen therapy to maintain saturation >90%
- Monitor: Temperature, respiratory rate, oxygen saturation at least twice daily 2
- Consider ICU if respiratory distress, altered consciousness, or hemodynamic instability
Prophylaxis for Exposed Contacts
Post-exposure prophylaxis 1, 6:
- Oseltamivir 75 mg once daily for 7-10 days after last exposure
- Indicated for extremely high-risk individuals (recent transplant, immunocompromised, pregnant)
- Begin as soon as exposure identified
Common Pitfalls to Avoid
- Delaying treatment beyond 48 hours in high-risk patients - treat anyway, as benefit likely persists 2, 6
- Using rapid antigen tests alone - sensitivity only 10-51%; negative test doesn't exclude H1N1 6. Confirm with RT-PCR when possible
- Prescribing antibiotics reflexively - reserve for documented bacterial superinfection 2
- Missing atypical presentations in immunocompromised (afebrile with rhinorrhea alone) 6
- Ignoring GI symptoms - diarrhea/vomiting may be the primary presentation 5
Prognosis
Most H1N1 cases are self-limited with symptom duration averaging 6-7 days 4. Mortality in critical cases reaches 44%, primarily in patients with chronic underlying diseases and multiple organ failure 7. Early antiviral treatment significantly reduces progression to severe disease.